Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review)
- Authors:
- Julie L. Hentze
- Claus K. Høgdall
- Estrid V. Høgdall
-
Affiliations: Department of Pathology, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark, Department of Gynecology, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark - Published online on: January 11, 2019 https://doi.org/10.3892/mco.2019.1800
- Pages: 323-330
This article is mentioned in:
Abstract
|
DGCG (2016–2017) DGCD årsreport. http://dgcg.dk/images/Grupper/Databasegruppen/rsrapport_DGCD_2016-17_endelig_anonymiseret.pdf | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Prat J: Figo Committee on Gynecologic Oncology: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hamilton W, Peters TJ, Bankhead C and Sharp D: Risk of ovarian cancer in women with symptoms in primary care: Population based case-control study. BMJ. 339:b29982009. View Article : Google Scholar : PubMed/NCBI | |
|
DGCG Ovariecancer guidelines. http://www.dgcg.dk/index.php/guidelines/ovariecancer-guidelinesJul 1–2016 | |
|
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C and Grudzinskas JG: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 97:922–929. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST and Farias-Eisner R: The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol. 199:215–223. 2008.PubMed/NCBI | |
|
Sundar S, Neal RD and Kehoe S: Diagnosis of ovarian cancer. BMJ. 351:h44432015. View Article : Google Scholar : PubMed/NCBI | |
|
Moss EL, Hollingworth J and Reynolds TM: The role of CA125 in clinical practice. J Clin Pathol. 58:308–312. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Meden H and Fattahi-Meibodi A: CA 125 in benign gynecological conditions. Int J Biol Markers. 13:231–237. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Buamah P: Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 75:264–265. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Rai N, Nevin J, Downey G, Abedin P, Balogun M, Kehoe S and Sundar S: Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 187:64–69. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, et al: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Martin LP and Schilder RJ: Management of recurrent ovarian carcinoma: Current status and future directions. Semin Oncol. 36:112–125. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wolffe AP and Matzke MA: Epigenetics: Regulation through repression. Science. 286:481–486. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Borgel J, Guibert S, Li Y, Chiba H, Schübeler D, Sasaki H, Forné T and Weber M: Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet. 42:1093–1100. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mohandas T, Sparkes RS and Shapiro LJ: Reactivation of an inactive human X chromosome: Evidence for X inactivation by DNA methylation. Science. 211:393–396. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 91:9700–9704. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao X, Cai F, Niu X, Shi H and Zhong Y: Association between P16INK4a promoter methylation and ovarian cancer: A meta-analysis of 12 published studies. PLoS One. 11:e01632572016. View Article : Google Scholar : PubMed/NCBI | |
|
Brait M, Ford JG, Papaiahgari S, Garza MA, Lee JI, Loyo M, Maldonado L, Begum S, McCaffrey L, Howerton M, et al: Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol Biomarkers Prev. 18:2984–2991. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Issa JP, Ahuja N, Toyota M, Bronner MP and Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61:3573–3577. 2001.PubMed/NCBI | |
|
Patra SK, Patra A, Zhao H and Dahiya R: DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 33:163–171. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H and Hirohashi S: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 105:527–532. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Feinberg AP and Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 301:89–92. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Ehrlich M: DNA methylation in cancer: Too much, but also too little. Oncogene. 21:5400–5413. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong Y, Dowdy SC, Xue A, Shujuan J, Eberhardt NL, Podratz KC and Jiang SW: Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecol Oncol. 96:601–609. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Eden A, Gaudet F, Waghmare A and Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 300:4552003. View Article : Google Scholar : PubMed/NCBI | |
|
Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H and Jaenisch R: Induction of tumors in mice by genomic hypomethylation. Science. 300:489–492. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:67–70. 1999.PubMed/NCBI | |
|
Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60:892–895. 2000.PubMed/NCBI | |
|
Talens RP, Boomsma DI, Tobi EW, Kremer D, Jukema JW, Willemsen G, Putter H, Slagboom PE and Heijmans BT: Variation, patterns, and temporal stability of DNA methylation: Considerations for epigenetic epidemiology. FASEB J. 24:3135–3144. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ and Widschwendter M: An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. 4:e82742009. View Article : Google Scholar : PubMed/NCBI | |
|
Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64:6476–6481. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Barton CA, Hacker NF, Clark SJ and O'Brien PM: DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 109:129–139. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Teschendorff AE, Jones A, Fiegl H, Sargent A, Zhuang JJ, Kitchener HC and Widschwendter M: Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med. 4:242012. View Article : Google Scholar : PubMed/NCBI | |
|
Teschendorff AE and Widschwendter M: Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics. 28:1487–1494. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, et al: Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. Clin Cancer Res. 23:2213–2222. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, et al: The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet. 8:e10025172012. View Article : Google Scholar : PubMed/NCBI | |
|
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Reyna-López GE, Simpson J and Ruiz-Herrera J: Differences in DNA methylation patterns are detectable during the dimorphic transition of fungi by amplification of restriction polymorphisms. Mol Gen Genet. 253:703–710. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Moelans CB, Atanesyan L, Savola SP and van Diest PJ: Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). Methods Mol Biol. 1708:537–549. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK and van den Boom D: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA. 102:15785–15790. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ziller MJ, Gu H, Müller F, Donaghey J, Tsai LT, Kohlbacher O, De Jager PL, Rosen ED, Bennett DA, Bernstein BE, et al: Charting a dynamic DNA methylation landscape of the human genome. Nature. 500:477–481. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S and Karlan BY: BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res. 60:5329–5333. 2000.PubMed/NCBI | |
|
Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B and Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 94:1396–1406. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 158:1121–1127. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y and Konishi I: Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 202:215–223. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z and Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 6:452007. View Article : Google Scholar : PubMed/NCBI | |
|
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, et al: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 20:1509–1518. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ozdemir F, Altinisik J, Karateke A, Coksuer H and Buyru N: Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med. 4:1092–1096. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65:8961–8967. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Czekierdowski A, Czekierdowska S, Szymanski M, Wielgos M, Kaminski P and Kotarski J: Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Neuro Endocrinol Lett. 27:609–613. 2006.PubMed/NCBI | |
|
Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, et al: OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet. 34:337–343. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I and Laird PW: Epigenetic stem cell signature in cancer. Nat Genet. 39:157–158. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Niskakoski A, Kaur S, Staff S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R and Peltomäki P: Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Epigenetics. 9:1577–1587. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, et al: Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer. 16:1022016. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Z, Li J, Han X, Hou H, Chen H, Zheng X, Lu J, Wang L, Chen W, Li X and Zhao L: TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells. J Exp Clin Cancer Res. 35:722016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Li X, Tian W, Wang Y, Wu D, Sun Z and Zhao E: Promoter DNA methylation is associated with KLF11 expression in epithelial ovarian cancer. Genes Chromosomes Cancer. 54:453–462. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Yu C, Zhou S, Lau WB, Lau B, Luo Z, Lin Q, Yang H, Xuan Y, Yi T, et al: Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling. Oncotarget. 7:1408–1420. 2016.PubMed/NCBI | |
|
Fu Y, Chen J, Pang B, Li C, Zhao J and Shen K: EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer. Cell Biochem Biophys. 71:105–112. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jacob F, Hitchins MP, Fedier A, Brennan K, Nixdorf S, Hacker NF, Ward R and Heinzelmann-Schwarz VA: Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells. BMC Mol Biol. 15:242014. View Article : Google Scholar : PubMed/NCBI | |
|
Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J and Shridhar V: Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene. 26:4969–4978. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Zhang S, Cui J, Zhang A, Shen L and Yu H: Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 48:505–509. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kanwal A, Kaur M, Singh A, Gupta S and Sachan M: Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population. Cell Mol Biol (Noisy-le-grand). 62:67–72. 2016.PubMed/NCBI | |
|
Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K and Karpf AR: PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget. 7:45352–45369. 2016.PubMed/NCBI | |
|
Melnikov A, Scholtens D, Godwin A and Levenson V: Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 11:60–65. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK and Levenson V: Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 120:113–120. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, Shen K and Kong B: A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 130:132–139. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xing BL, Li T, Tang ZH, Jiao L, Ge SM, Qiang X and OuYang J: Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer. Genet Mol Res. 14:4532–4540. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Yu L, Yang GZ, Luo X and Huang L: Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 16:3003–3007. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Yu L, Luo X, Huang L, Li QS, Shao XS, Liu Y, Fan Y and Yang GZ: Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. Oncol Lett. 14:217–223. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Koestler DC, Chalise P, Cicek MS, Cunningham JM, Armasu S, Larson MC, Chien J, Block M, Kalli KR, Sellers TA, et al: Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Med Genomics. 7:82014. View Article : Google Scholar : PubMed/NCBI | |
|
Winham SJ, Armasu SM, Cicek MS, Larson MC, Cunningham JM, Kalli KR, Fridley BL and Goode EL: Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol. 38:457–466. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W and Chen K: DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. 38:797–805. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ and Widschwendter M: HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int J Cancer. 123:725–729. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, et al: Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol. 124:582–588. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, et al: HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. Int J Cancer. 125:2214–2218. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Häfner N, Steinbach D, Jansen L, Diebolder H, Dürst M and Runnebaum IB: RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer. Int J Cancer. 138:217–228. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Deng Z, Wang L, Hou H, Zhou J and Li X: Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/β-catenin signaling. Int J Oncol. 48:153–160. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW, Knudsen S, Hansen A, Jensen PB, Jensen T, Mirza MR, et al: Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS One. 12:e01743002017. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S and Scambia G: p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer. 81:733–740. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, et al: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 7:2984–2997. 2001.PubMed/NCBI | |
|
Sung HY, Yang SD, Ju W and Ahn JH: Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer. Exp Mol Med. 49:e3352017. View Article : Google Scholar : PubMed/NCBI | |
|
Sung HY, Yang SD, Park AK, Ju W and Ahn JH: Aberrant hypomethylation of solute carrier family 6 member 12 promoter induces metastasis of ovarian cancer. Yonsei Med J. 58:27–34. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sung HY, Choi EN, Lyu D, Park AK, Ju W and Ahn JH: Aberrant hypomethylation-mediated AGR2 overexpression induces an aggressive phenotype in ovarian cancer cells. Oncol Rep. 32:815–820. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sung HY, Park AK, Ju W and Ahn JH: Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells. Yonsei Med J. 55:1206–1213. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sung HY, Ju W and Ahn JH: DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells. Yonsei Med J. 55:1656–1663. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K and Karpf AR: DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics. 10:736–748. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kohler RS, Anugraham M, López MN, Xiao C, Schoetzau A, Hettich T, Schlotterbeck G, Fedier A, Jacob F and Heinzelmann-Schwarz V: Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients. Oncotarget. 7:51674–51686. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP and Matei D: TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics. 9:1461–1472. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, et al: Recruitment to multicentre trials-lessons from UKCTOCS: Descriptive study. BMJ. 337:a20792008. View Article : Google Scholar : PubMed/NCBI | |
|
Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P and Verheijen RH: Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 195:451–456. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Finch A, Shaw P, Rosen B, Murphy J, Narod SA and Colgan TJ: Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 100:58–64. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 31:161–169. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM and Vang R: Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 34:1407–1416. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL and Shih IeM: TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 226:421–426. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, et al: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 24:751–765. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS and Muto MG: Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 25:3985–3990. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW and Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 30:230–236. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, et al: Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nat Commun. 7:116202016. View Article : Google Scholar : PubMed/NCBI | |
|
Doufekas K, Zheng SC, Ghazali S, Wong M, Mohamed Y, Jones A, Reisel D, Mould T, Olaitan A, Macdonald N, et al: DNA methylation signatures in vaginal fluid samples for detection of cervical and endometrial cancer. Int J Gynecol Cancer. Jun 2–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP and Matei D: Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 74:4922–4936. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cacan E: Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells. Cell Biol Int. 41:328–339. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yan B, Yin F, Wang QI, Zhang W and Li LI: Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett. 12:157–166. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cacan E: Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 29:173–178. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, et al: Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. 15:1162017. View Article : Google Scholar : PubMed/NCBI | |
|
Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, Moulder R, Goodlett DR, Lahesmaa R and Carpén O: DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer. Sci Rep. 7:14692017. View Article : Google Scholar : PubMed/NCBI | |
|
Bonito NA, Borley J, Wilhelm-Benartzi CS, Ghaem-Maghami S and Brown R: Epigenetic regulation of the homeobox gene MSX1 associates with platinum-resistant disease in high-grade serous epithelial ovarian cancer. Clin Cancer Res. 22:3097–3104. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
de Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, Nephew K and Matei D: Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol. 142:539–547. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, et al: HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med. 7:1082015. View Article : Google Scholar : PubMed/NCBI | |
|
Han X, Zhou Y, You Y, Lu J, Wang L, Hou H, Li J, Chen W, Zhao L and Li X: TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. Cell Biol Int. 41:405–414. 2017. View Article : Google Scholar : PubMed/NCBI |
